Clinical Trials Browser

Phase 2 × Hodgkin Disease × umbralisib × Clear all

NCT03776864 2023-05-03

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 2 Terminated

6 enrolled 8 charts

Hodgkin Disease